Your browser doesn't support javascript.
loading
Bufalin serves as a pharmaceutic that mitigates drug resistance.
Miao, Linxuan; Liu, Ying; Ali, Nasra Mohamoud; Dong, Yan; Zhang, Bin; Cui, Xiaonan.
Afiliação
  • Miao L; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, P.R. China.
  • Liu Y; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, P.R. China.
  • Ali NM; Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, P.R. China.
  • Dong Y; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, P.R. China.
  • Zhang B; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, P.R. China.
  • Cui X; Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, P.R. China.
Drug Metab Rev ; 55(3): 195-204, 2023 08.
Article em En | MEDLINE | ID: mdl-37114332
Intrinsic or acquired drug resistance of tumor cells is the main cause of tumor chemotherapy failure and tumor-related death. Bufalin (BF) is the main active monomer component extracted from the Traditional Chinese Medicine Toad venom (secretions of glands behind the ears and epidermis of bufo gargarizans and Bufo Melanostictus Schneider). It is a cardiotonic steroid with broad-spectrum anti-cancer effects and has been widely used against various malignant tumors in clinical practice. Pharmacological studies also found that BF has the effect of reversing drug resistance, which provides a new perspective for the application of Traditional Chinese Medicine as a chemosensitizer in cancer therapy. This article provides an extensive search and summary of published research on mitigating drug resistance to BF and reviews its potential mechanisms.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bufanolídeos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bufanolídeos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article